
Revolution Medicines' cancer drug Rasonque posts record $198M launch in 5 weeks, boosting valuation prospects.
Revolution Medicines' pancreatic cancer drug Rasonque achieved a historic launch, generating $198 million in revenue within five weeks after its late August approval. The drug outperformed standard chemotherapy in Phase 3 trials, doubling median surv...



